Another study with a super mutant IL-2 (sumIL-2) with decreased CD25 binding and increased CD122 (βIL-2R) binding, fused to a tumor-targeting antibody, revealed the therapeutic potential of antibody-cytokine fusion proteins comprising next-generation IL-2. This evidence concerns the gene IL2 and neoplasm.